Literature DB >> 19366353

Pentameric concatenated (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) nicotinic acetylcholine receptors: subunit arrangement determines functional expression.

A-L Carbone1, M Moroni, P-J Groot-Kormelink, I Bermudez.   

Abstract

BACKGROUND AND
PURPOSE: alpha4 and beta2 nicotinic acetylcholine (ACh) receptor subunits expressed heterologously in Xenopus oocytes assemble into a mixed population of (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) receptors. In order to express these receptors separately in heterologous systems, we have engineered pentameric concatenated (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) receptors. EXPERIMENTAL APPROACH: alpha4 and beta2 subunits were concatenated by synthetic linkers into pentameric constructs to produce either (alpha4)(2)(beta2)(3) or (alpha4)(3)(beta2)(2) receptors. Using two-electrode voltage-clamp techniques, we examined the ability of the concatenated constructs to produce functional expression in Xenopus oocytes. Functional constructs were further characterized in respect to agonists, competitive antagonists, Ca2+ permeability, sensitivity to modulation by Zn2+ and sensitivity to up-regulation by chaperone protein 14-3-3. KEY
RESULTS: We found that pentameric concatamers with a subunit arrangement of beta2_alpha4_beta2_alpha4_beta2 or beta2_alpha4_beta2_alpha4_alpha4 were stable and functional in Xenopus oocytes. By comparison, when alpha4 and beta2 were concatenated with a subunit order of beta2_beta2_alpha4_beta2_alpha4 or beta2_alpha4_alpha4_beta2_alpha4, functional expression in Xenopus oocytes was very low, even though the proteins were synthesized and stable. Both beta2_alpha4_beta2_alpha4_beta2 and beta2_alpha4_beta2_alpha4_alpha4 concatamers recapitulated the ACh concentration response curve, the sensitivity to Zn2+ modulation, Ca2+ permeability and the sensitivity to up-regulation by chaperone protein 14-3-3 of the corresponding non-linked (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) receptors respectively. Using these concatamers, we found that most alpha4beta2-preferring compounds studied, including A85380, 5I-A85380, cytisine, epibatidine, TC2559 and dihydro-beta-erythroidine, demonstrate stoichiometry-specific potencies and efficacies. CONCLUSIONS AND IMPLICATIONS: We concluded that the alpha4beta2 nicotinic ACh receptors produced with beta2_alpha4_beta2_alpha4_beta2 or beta2_alpha4_beta2_alpha4_alpha4 pentameric constructs are valid models of non-linked (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) receptors respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366353      PMCID: PMC2697715          DOI: 10.1111/j.1476-5381.2008.00104.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Constraining the expression of nicotinic acetylcholine receptors by using pentameric constructs.

Authors:  Paul J Groot-Kormelink; Steven Broadbent; Marco Beato; Lucia G Sivilotti
Journal:  Mol Pharmacol       Date:  2005-11-03       Impact factor: 4.436

Review 2.  Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

Authors:  Cecilia Gotti; Michele Zoli; Francesco Clementi
Journal:  Trends Pharmacol Sci       Date:  2006-07-31       Impact factor: 14.819

3.  Impact of subunit positioning on GABAA receptor function.

Authors:  E Sigel; R Baur; N Boulineau; F Minier
Journal:  Biochem Soc Trans       Date:  2006-11       Impact factor: 5.407

Review 4.  From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research.

Authors:  Bruce K Cassels; Isabel Bermúdez; Federico Dajas; J Andrés Abin-Carriquiry; Susan Wonnacott
Journal:  Drug Discov Today       Date:  2005-12       Impact factor: 7.851

5.  alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine.

Authors:  Mirko Moroni; Ruud Zwart; Emanuele Sher; Bruce K Cassels; Isabel Bermudez
Journal:  Mol Pharmacol       Date:  2006-05-23       Impact factor: 4.436

6.  A GABA(A) receptor of defined subunit composition and positioning: concatenation of five subunits.

Authors:  Roland Baur; Frédéric Minier; Erwin Sigel
Journal:  FEBS Lett       Date:  2006-02-17       Impact factor: 4.124

7.  Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors.

Authors:  A Kuryatov; J Luo; J Cooper; J Lindstrom
Journal:  Mol Pharmacol       Date:  2005-09-23       Impact factor: 4.436

8.  Chaperone protein 14-3-3 and protein kinase A increase the relative abundance of low agonist sensitivity human alpha 4 beta 2 nicotinic acetylcholine receptors in Xenopus oocytes.

Authors:  Richard Exley; Mirko Moroni; Federica Sasdelli; Lee M Houlihan; Ronald J Lukas; Emanuele Sher; Ruud Zwart; Isabel Bermudez
Journal:  J Neurochem       Date:  2006-06-19       Impact factor: 5.372

9.  Tandem subunits effectively constrain GABAA receptor stoichiometry and recapitulate receptor kinetics but are insensitive to GABAA receptor-associated protein.

Authors:  Andrew J Boileau; Robert A Pearce; Cynthia Czajkowski
Journal:  J Neurosci       Date:  2005-12-07       Impact factor: 6.167

10.  5-I A-85380 and TC-2559 differentially activate heterologously expressed alpha4beta2 nicotinic receptors.

Authors:  Ruud Zwart; Lisa M Broad; Qian Xi; Martin Lee; Mirko Moroni; Isabel Bermudez; Emanuele Sher
Journal:  Eur J Pharmacol       Date:  2006-04-05       Impact factor: 4.432

View more
  70 in total

1.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.

Authors:  Amir H Rezvani; Marty Cauley; Hannah Sexton; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

2.  α7β2 nicotinic acetylcholine receptors assemble, function, and are activated primarily via their α7-α7 interfaces.

Authors:  Teresa A Murray; Daniel Bertrand; Roger L Papke; Andrew A George; Rigo Pantoja; Rahul Srinivasan; Qiang Liu; Jie Wu; Paul Whiteaker; Henry A Lester; Ronald J Lukas
Journal:  Mol Pharmacol       Date:  2011-10-28       Impact factor: 4.436

Review 3.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

4.  Function of human α3β4α5 nicotinic acetylcholine receptors is reduced by the α5(D398N) variant.

Authors:  Andrew A George; Linda M Lucero; M Imad Damaj; Ronald J Lukas; Xiangning Chen; Paul Whiteaker
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

5.  Alpha-conotoxin AuIB isomers exhibit distinct inhibitory mechanisms and differential sensitivity to stoichiometry of alpha3beta4 nicotinic acetylcholine receptors.

Authors:  Anton A Grishin; Ching-I A Wang; Markus Muttenthaler; Paul F Alewood; Richard J Lewis; David J Adams
Journal:  J Biol Chem       Date:  2010-05-13       Impact factor: 5.157

6.  Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers.

Authors:  Alexandre Kuryatov; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2010-10-05       Impact factor: 4.436

7.  Modulation of recombinant, α2*, α3* or α4*-nicotinic acetylcholine receptor (nAChR) function by nAChR β3 subunits.

Authors:  Bhagirathi Dash; Minoti Bhakta; Yongchang Chang; Ronald J Lukas
Journal:  J Neurochem       Date:  2012-03-14       Impact factor: 5.372

8.  Differential α4(+)/(-)β2 Agonist-binding Site Contributions to α4β2 Nicotinic Acetylcholine Receptor Function within and between Isoforms.

Authors:  Linda M Lucero; Maegan M Weltzin; J Brek Eaton; John F Cooper; Jon M Lindstrom; Ronald J Lukas; Paul Whiteaker
Journal:  J Biol Chem       Date:  2015-12-07       Impact factor: 5.157

9.  Potentiation of a neuronal nicotinic receptor via pseudo-agonist site.

Authors:  Simone Mazzaferro; Isabel Bermudez; Steven M Sine
Journal:  Cell Mol Life Sci       Date:  2019-01-01       Impact factor: 9.261

10.  Non-equivalent ligand selectivity of agonist sites in (α4β2)2α4 nicotinic acetylcholine receptors: a key determinant of agonist efficacy.

Authors:  Simone Mazzaferro; Federica Gasparri; Karina New; Constanza Alcaino; Manuel Faundez; Patricio Iturriaga Vasquez; Ranjit Vijayan; Philip C Biggin; Isabel Bermudez
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.